GPs urged to review asthma prescribing

More than 22,000 people with asthma have been prescribed long-acting reliever inhalers without an inhaled corticosteroid, a report by Asthma UK highlights.

 Patients using a short-acting reliever inhaler more than three times a week are at increased risk of an asthma attack. | SCIENCE PHOTO LIBRARY
Patients using a short-acting reliever inhaler more than three times a week are at increased risk of an asthma attack. | SCIENCE PHOTO LIBRARY

Monotherapy with long-acting reliever inhalers, either long-acting beta agonists (LABAs) or long-acting muscarinic antagonists (LAMAs), increases the risk of a life-threatening asthma attack.

Long-acting relievers keep airways opened up but do not treat the underlying inflammation, which gets progressively worse without steroid treatment. Inflamed airways make the patient more likely to react to their asthma triggers.

Current guidelines emphasise that long-acting relievers must be taken with a steroid preventer inhaler or as a combination inhaler. Combination inhalers are recommended to ensure that the reliever is not taken without the corticosteroid

The report also found that over 100,000 asthma patients have been prescribed more than 12 short-acting reliever inhalers over 12 months. Such high usage is strongly suggestive of poor asthma control and a predictor of future asthma attacks.

Asthma UK urges prescribers to: 

  • Identify patients with asthma on long-acting reliever inhalers who have not been prescribed an inhaled corticosteroid and call them in for an urgent review.
  • Be aware than any patient who is prescribed more than 12 short-acting reliever inhalers in a year is at increased risk of an asthma attack and requires prompt review.
  • Personally invite the above patients for reviews by phone, text or email. Adding a note through the Electronic Prescription Service can also reinforce the message.
  • Audit prescribing of LABAs and LAMAs and high numbers of short-acting reliever inhalers.
  • Consider switching from repeat to acute prescribing for patients with asthma, so future prescriptions can only be issued after a review.

The report follows last year’s National Review of Asthma Deaths, which identified prescribing errors in 47% of asthma deaths in primary care.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases